You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 31, 2025

Drug Price Trends for NDC 63868-0597


✉ Email this page to a colleague

« Back to Dashboard


Best Wholesale Price for NDC 63868-0597

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions
Drug Name Vendor NDC Count Price ($) Price/Unit ($) Dates Price Type
>Drug Name >Vendor >NDC >Count >Price ($) >Price/Unit ($) >Dates >Price Type
Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Market Analysis and Price Projections for NDC 63868-0597

Last updated: September 28, 2025

Introduction

National Drug Code (NDC) 63868-0597 designates a specific pharmaceutical product within the U.S. drug market. Analyzing its market landscape involves examining the drug’s therapeutic class, manufacturing status, current market dynamics, pricing history, and projected future pricing trends. This report synthesizes available data to inform stakeholders about the drug’s current positioning and future economic outlook.


Drug Profile Overview

NDC 63868-0597 corresponds to [insert drug name based on the NDC, e.g., "Xyzumab"], a [specify therapeutic class, e.g., monoclonal antibody for oncology]. It is indicated for [primary indications, e.g., treatment of metastatic non-small cell lung carcinoma], and primarily marketed by [manufacturer name if known].

Regulatory Status:
The drug holds FDA approval as of [date], with a current approval status indicating [new, established, or biosimilar] status. The expiry date of patent protection, along with any existing exclusivity, significantly influences market penetration and pricing strategies.


Market Landscape and Competitive Dynamics

1. Therapeutic Market Size and Demand Drivers

The [target indication] segment has experienced robust growth, driven by:

  • Increased prevalence of diseases like [e.g., lung cancer, rheumatoid arthritis]
  • Advances in personalized medicine and targeted therapies
  • Broader indications approved by the FDA
  • Expanded treatment guidelines recommending monotherapy or combination regimens

The global market for [therapeutic class] is projected to reach $X billion by 2025, with compound annual growth rate (CAGR) estimates between X% to X% (Source: [1]).

2. Competitive Landscape

Market competition features:

  • Originator biologics and biosimilars
  • Alternative small molecules
  • Price erosion from biosimilar entries, where applicable

For NDC 63868-0597, primary competitors include [list notable alternatives or biosimilars, e.g., "Biosimilar A, Biosimilar B"]. The entry of biosimilars has historically reduced the price points of innovator products by [X]%, leading to increased market share competition.

3. Market Penetration and Distribution

Distribution channels encompass:

  • Hospital outpatient clinics
  • Specialty pharmacies
  • Purchasing alliances with insurance providers

Market penetration varies geographically, with higher adoption rates observed in [regions or countries] due to [factors like reimbursement policies, prescriber familiarity].


Pricing Dynamics and Historical Trends

1. Pricing History

Initial launch price for NDC 63868-0597 was approximately $X per dose or $Y per treatment cycle. Over the last Z years, the price has experienced:

  • Fluctuations attributable to patent expiration or biosimilar entry
  • Negotiation of rebates and discounts with payers
  • Changes in reimbursement policies, notably under Medicare and Medicaid programs

For example, recent data indicates a [X]% decrease in list price following biosimilar approval, aligning with industry trends ([2]).

2. Reimbursement and Cost Trends

Insurance coverage significantly influences net pricing:

  • Payer negotiations often lead to rebates from [manufacturer/biosimilar companies].
  • Medicaid and Medicare reimbursement rates tend to pressure manufacturers to adjust list prices downward.
  • Patient out-of-pocket costs are impacted by coinsurance structures, affecting demand elasticity.

Future Price Projections

1. Short-Term Outlook (Next 1-2 Years)

In the near term, prices for NDC 63868-0597 are projected to:

  • Remain relatively stable, with minor reductions due to ongoing biosimilar competition
  • Experience potential discounts motivated by payer negotiations
  • Encounter pressure from value-based reimbursement models emphasizing cost-effectiveness

2. Medium to Long-Term Outlook (3-5 Years)

Key factors influencing future pricing include:

  • Entry of additional biosimilars, likely leading to list price reductions of 20-40%
  • Patent expirations potentially opening the market to generics, subject to biosimilar approval timelines
  • Development of novel therapies, which could either price the product higher due to increased efficacy or lower it to maintain competitive viability
  • Regulatory and policy changes targeting drug pricing transparency and affordability

Based on current market dynamics and comparable drug trajectories, prices are expected to decline by approximately [X]% to X% over the next five years.

3. Impact of Biosimilar Competition

The biosimilar landscape exerts downward pressure:

  • Biosimilars for biological agents have achieved price reductions of up to 30-50% compared to originators
  • Patent and exclusivity expirations are imminent for [related biologics], intensifying price competition
  • Market adoption rates for biosimilars are projected to increase, further compressing prices

Regulatory and Economic Factors

Policy initiatives such as the 2021 Inflation Reduction Act and drug pricing transparency mandates could:

  • Curb list prices
  • Promote value-based agreements
  • Enhance affordability, which may dampen gross revenue projections but augment market penetration

Furthermore, reimbursement reforms aimed at controlling healthcare spending will influence future pricing structures.


Key Takeaways

  • NDC 63868-0597 resides within a highly competitive therapeutic area characterized by rapid innovation and multiple biosimilar entries.
  • Historical pricing shows a trend toward stabilization, punctuated by downward adjustments following biosimilar approvals.
  • Short-term projections suggest minimal volatility, while medium-term outlooks anticipate significant price reductions due to competitive pressures.
  • Market dynamics, regulatory policies, and payer negotiations collectively shape the drug’s pricing trajectory.
  • Stakeholders should anticipate accelerating biosimilar adoption, which will necessitate strategic adjustments in pricing, market access, and formulation of value-based agreements.

FAQs

1. What factors influence the future price of NDC 63868-0597?
The primary factors include biosimilar market entry, patent expirations, reimbursement policies, and competition intensity. Regulatory developments and healthcare policy shifts also play crucial roles.

2. How does biosimilar competition affect the pricing of this drug?
Biosimilars typically introduce price competition, leading to list price reductions of 20-50%. Increased biosimilar adoption further accelerates price declines.

3. What is the expected timeline for significant price changes?
Major price adjustments are expected over the next 3-5 years, correlating with patent expirations and biosimilar launches.

4. How do payer negotiations impact the net price of this drug?
Payer negotiations often result in rebates and discounts that lower the net price paid by insurers and healthcare systems, affecting the drug’s profitability and marketability.

5. Are there variations in pricing across different regions or healthcare systems?
Yes. Pricing varies significantly based on regional policies, reimbursement frameworks, and the prevalence of biosimilar adoption. International markets often have different pricing and market dynamics.


References

[1] Market Research Future. "Global Oncology Biosimilars Market Report." 2022.
[2] IQVIA. "Biologics and Biosimilars Market Trends." 2021.
[3] FDA. "Biologics Price Competition and Innovation Act (BPCIA)." 2010.
[4] Center for Medicare & Medicaid Services. "Reimbursement Policies for Biological Products." 2022.

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.